Incyte

News

Incyte builds GvHD presence with Niktimvo approval

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder.

News

CHMP backs AZ’s danicopan for anaemia in patients with PNH

AstraZeneca has moved a step closer to EU approval of oral Factor D inhibitor danicopan in the EU, after the EMA’s human medicines committee, the CHMP, backed the drug as

News

Novartis calls time on Tim3 drug sabatolimab in MDS

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate.

News

Eisai files biliary tract cancer drug tasurgratinib in Japan

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers wit

News

Incyte’s oral vitiligo drug heading for phase 3

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in pati

News